Doximity Countersues OpenEvidence, Alleges Misinformation Campaign and Harassment
BOSTON – A legal battle between medical technology companies Doximity Inc. and OpenEvidence Inc. has intensified, with Doximity filing counterclaims alleging a wide-ranging campaign of misinformation, harassment, and patient data privacy violations by OpenEvidence. The countersuit, filed in the US District Court for the District of Massachusetts, follows an initial lawsuit by OpenEvidence alleging misappropriation of trade secrets. Doximity vehemently denies these claims and now accuses OpenEvidence of engaging in a systematic effort to damage its reputation and disrupt its operations.
Doximity’s counterclaims paint a picture of a calculated and aggressive campaign orchestrated by OpenEvidence and its founder, Daniel Nadler. The filing alleges that OpenEvidence repeatedly disseminated false information about Doximity and its services, including misleading claims about its data security practices. Specifically, Doximity contends that OpenEvidence falsely advertised its own platform as secure for user and patient information while simultaneously accusing Doximity of lax security protocols. The counterclaims also detail a series of “strange” emails allegedly sent by Nadler to Doximity’s general counsel, which Doximity characterizes as taunting and unprofessional.
Further escalating the dispute, Doximity accuses OpenEvidence of engaging in a relentless campaign to poach its employees. The counterclaims allege that OpenEvidence bombarded Doximity employees with unsolicited text messages promising exorbitant, million-dollar bonuses. Doximity contends that this aggressive recruitment tactic was not only unethical but also disruptive to its workforce and business operations. The majority of these attempts were reportedly unsuccessful, but Doximity argues that the sheer volume and persistence of these solicitations constitute harassment.
The most serious allegation in Doximity’s counterclaims is the accusation that OpenEvidence publicly disclosed confidential patient information. While the filing does not provide specific details about the nature or extent of the alleged disclosure, it asserts that OpenEvidence’s actions violated patient privacy and potentially jeopardized sensitive medical data. This claim raises significant concerns about the handling of confidential patient information and the potential legal and ethical ramifications for OpenEvidence.
This escalating legal conflict represents a significant clash between two prominent players in the digital health sector. Doximity, primarily known for its professional networking platform for physicians, and OpenEvidence, a healthcare data analytics company, are now locked in a bitter dispute that extends beyond intellectual property rights into allegations of corporate espionage, harassment, and patient privacy violations. The outcome of this case could have substantial implications for both companies and the broader medical technology industry.
The court will now have to navigate these complex allegations and determine the validity of the claims and counterclaims. The discovery process is expected to be extensive, potentially involving the examination of internal communications, employee testimonies, and technical data related to both companies’ platforms. The legal battle promises to be a protracted and closely watched affair, offering a glimpse into the competitive dynamics and ethical challenges within the rapidly evolving landscape of digital health. The case also highlights the increasing importance of data security and patient privacy in the digital age, underscoring the need for robust safeguards and ethical practices within the healthcare technology sector.
